0001193125-24-164545.txt : 20240620 0001193125-24-164545.hdr.sgml : 20240620 20240620165937 ACCESSION NUMBER: 0001193125-24-164545 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240619 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240620 DATE AS OF CHANGE: 20240620 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vanda Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001347178 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 030491827 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34186 FILM NUMBER: 241057247 BUSINESS ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE NW STREET 2: SUITE 300E CITY: WASHINGTON STATE: DC ZIP: 20037 BUSINESS PHONE: 202-734-3400 MAIL ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE NW STREET 2: SUITE 300E CITY: WASHINGTON STATE: DC ZIP: 20037 8-K 1 d844822d8k.htm 8-K 8-K
false 0001347178 0001347178 2024-06-19 2024-06-19 0001347178 us-gaap:CommonStockMember 2024-06-19 2024-06-19 0001347178 vnda:SeriesAJuniorParticipatingPreferredStockPurchaseRightMember 2024-06-19 2024-06-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 20, 2024 (June 19, 2024)

 

 

VANDA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   001-34186   03-0491827
(State or other jurisdiction
of incorporation)		  

(Commission

File No.)

   (IRS Employer
Identification No.)

2200 Pennsylvania Avenue NW

Suite 300E

Washington, DC 20037

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (202) 734-3400

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   VNDA   The Nasdaq Global Market
Series A Junior Participating Preferred Stock Purchase Right, par value $0.001 per share   —    The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01.

Other Events.

On June 19, 2024, Vanda Pharmaceuticals Inc., a Delaware corporation, issued a press release announcing that its Board of Directors, in consultation with its independent financial and legal advisors, and consistent with its fiduciary duties, rejected unsolicited acquisition proposals from Future Pak, LLC and Cycle Group Holdings Ltd. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.		    Description
99.1    Press release of Vanda Pharmaceuticals Inc. dated June 19, 2024.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 20, 2024     VANDA PHARMACEUTICALS INC.
    By:  

/s/ Timothy Williams

    Name:   Timothy Williams
    Title:   Senior Vice President, General Counsel and Secretary
 EX-99.1 2 d844822dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover

Proposals Are Not in the Best Interests of the Company and its Shareholders

WASHINGTON, June 19, 2024 /PRNewswire/ – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company’s Board of Directors (the “Board”), following careful review and consultation with its independent financial and legal advisors, has determined that the unsolicited proposal from Cycle Group Holdings Ltd (“Cycle Group”) to acquire Vanda for $8.00 per share in cash and the revised unsolicited proposal from Future Pak, LLC (“FP”) to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights (“CVRs”) both substantially undervalue Vanda and are not in the best interests of the Company and its shareholders. Accordingly, the Board has rejected the proposals.

The Vanda Board again evaluated all aspects of Vanda’s business against the unsolicited proposals and determined that the proposals are opportunistic attempts to purchase the Company’s shares at a discount to Vanda’s intrinsic value. The Board’s prior analysis of the company’s clinical development pipeline, expanding commercial presence and significant cash balance remains unchanged. The Board also reached the same conclusion as it reached previously regarding the speculative nature of the CVRs given the uncertainty surrounding the achievement of the commercial milestones under FP’s management.

The Board and management team remain confident that Vanda’s robust revenue, strong cash position and efficient operations position the Company well for significant long-term growth and value creation far in excess of the consideration offered by Cycle Group and FP.

There is no action for shareholders to take at this time.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

Various statements in this press release, including, but not limited to, statements regarding the Board’s assessment of the Cycle Group and FP proposals and the confidence that the Board and management team have in the Company’s long-term prospects for growth and value creation, are “forward-looking statements” under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda’s business and market, particularly those identified in the “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s most recent Annual Report on Form 10-K, as updated by Vanda’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.

Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Corporate Contact:

Kevin Moran

Senior Vice President, Chief Financial Officer and Treasurer

Vanda Pharmaceuticals Inc.

202-734-3400

pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore

Collected Strategies

VANDA-CS@collectedstrategies.com

EX-101.SCH 3 vnda-20240619.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 vnda-20240619_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 vnda-20240619_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Series A Junior Participating Preferred Stock Purchase Right [Member] Series A Junior Participating Preferred Stock Purchase Right [Member] EX-101.PRE 6 vnda-20240619_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g844822g0620151835425.jpg GRAPHIC begin 644 g844822g0620151835425.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 19, 2024
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001347178
Document Type 8-K
Document Period End Date Jun. 19, 2024
Entity Registrant Name VANDA PHARMACEUTICALS INC.
Entity Incorporation State Country Code DE
Entity File Number 001-34186
Entity Tax Identification Number 03-0491827
Entity Address, Address Line One 2200 Pennsylvania Avenue NW
Entity Address, Address Line Two Suite 300E
Entity Address, City or Town Washington
Entity Address, State or Province DC
Entity Address, Postal Zip Code 20037
City Area Code (202)
Local Phone Number 734-3400
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol VNDA
Security Exchange Name NASDAQ
Series A Junior Participating Preferred Stock Purchase Right [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Series A Junior Participating Preferred Stock Purchase Right, par value $0.001 per share
Trading Symbol — 
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 3 23 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d844822d8k.htm vnda-20240619.xsd vnda-20240619_def.xml vnda-20240619_lab.xml vnda-20240619_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d844822d8k.htm": { "nsprefix": "vnda", "nsuri": "http://www.vandapharmaceuticals.com/20240619", "dts": { "inline": { "local": [ "d844822d8k.htm" ] }, "schema": { "local": [ "vnda-20240619.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "definitionLink": { "local": [ "vnda-20240619_def.xml" ] }, "labelLink": { "local": [ "vnda-20240619_lab.xml" ] }, "presentationLink": { "local": [ "vnda-20240619_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-06-19_to_2024-06-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d844822d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-06-19_to_2024-06-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d844822d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "vnda_DocumentAndEntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240619", "localname": "DocumentAndEntityInformationLineItems", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "auth_ref": [] }, "vnda_DocumentAndEntityInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240619", "localname": "DocumentAndEntityInformationTable", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vandapharmaceuticals.com/20240619", "localname": "SeriesAJuniorParticipatingPreferredStockPurchaseRightMember", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Series A Junior Participating Preferred Stock Purchase Right [Member]", "terseLabel": "Series A Junior Participating Preferred Stock Purchase Right [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.vandapharmaceuticals.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001193125-24-164545-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-164545-xbrl.zip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

  • GF3)4107RI3L#K M?Y&-*Y85R1WA66^%UP3YX%HCB(1M5@'R$F!J@"KB#7"+K9=!;MZ_']+G/%SI MN9FJ[EU)WL[I"&!KXWQWGP^NNSI(E!;"H)6]T<1OLTRD8Z\X&-X007ETP:)S M]7ZF*8_/DCL&TVZ%UP1AH&H1Q&8V*P&J!N@B:/BVT+J58^?^,18+7\B"ZD4R M2S\'B3/1]MQ.EPH51GAUC/]"P::'NTYXJ@"Z!-(JH8V^+8L$Y^8Q0+YD(1=+ M+LREDMM4#9N-KESBO\0.,CCSL1603 5(2\)NB;2 MD+R +\O,'&X.8X@^TIA\7B4S(II-3#FOT_&P&.#V_?[@/]?"I5RK0R:/!#1V MOQ9ZG9K& '4:K"\CM5BB9XT[!/O#72N,2[HJ!=NU<+EO MU8IE" [P@S$2DRA2!F3^UQ5E9-1L'*P"G8Y"G26^)]!_!"I%'_M@5_7$;Z(]?#OWI V\-?20;SNC7>D%$ M_TR]O!93_L . K^<_AJPM]BQ0?\4AH;\<\F6@-=E@ O0A7!AQS90A[J;"T3, MS?OA:W$C^#UE87S:]QVA5>PRC83=D&82L2;0PLJBT-058)5"G,ZY;MV:@; M &I(N&MRD"Y#F2% MP%3R!KUM$V7@#W2"BOZEE"LB_ ? HO,ZQJ#:H'T8=N(11Z)"NZW!R,JU.A\M M.:J=DD:V/)MJ:5-E@-OW>RUKK%I8BYI<')0Z M&'G_-4TK_6ZM:!HT[0?J5 3Z6?/;33+CSDOP9TD=(6IOG5MV^L!I$4(B,U>& M3-J;RA8:+2/IVBW.>?-B'=XIMZ3)PPSVW([/GU8CO#H&XSRZJX=]+BTJX#S, MT%[?UG.J8_,8G^]=)$0LU-3\*?A#>J<6(\N -7R0MT*BTT_XZFWQO:'^G_'5 MR"*QGG\P5A2"K!+DI9 ^XVO1AN5#OL9>GHW /8L"3?FO1[^/WAK2]9;'Y^HF M+"J>N)ASD9CKA]-@YK;X=57J@/N&)KEKQJ%3T$0=:1@>GVE4Y>#Q"9?'@O#5 ME/3[.I&7M&5]7O-0;_Y35;AI29' MEP53M^7Q0?;7:(2<3-8MN.:!G)D&5K*_"()EMNHB<2J++4_+KWS#-W,OEV[K M+ ZDO)[?ICS\/EE3IRES$.E@N-RM<8?@0T?)41AI@HPX\#D8>?BJ"_B-R@OU MOW4S2S,3V*-0-GC.DX ZW5Y>E]TA_#5F>%V4+^Y5BBUQGI7 (;VMUNL0W]L_ M.N0\2?03WJKZ)^)Z+U=-(5UKA-4'>@-L%L?@VZ@4=60$DNMOI>_N+"!LU M[_:6X)8(2N3DGRM&N;@)1$I#N@ST?0PW*HT(02)3\$9U?A=(8KX-U1UM_QI= MO7W .##<7\OKK89W7;1KMKH/F$#6"6RU H^]Y&@7W63?O(LSIJ_C<&Q?"F[C MF)0WJ#<\W_4W%>>;:/9]O6K+_P%02P,$% @ <8?46*O*C5FE!0 W3D M !4 !V;F1A+3(P,C0P-C$Y7W!R92YX;6S=FVUSXC80Q]_?S'T'U7W3SM0X M-LFU84)N*$DZM,F%"5S;Z9N,L!?0G"QY))/ M^_*H!X&0\REO43-9'B0M:O] M[T^6)=F^3BZO>!^*3:9YGNA4$CX^/C63,A)9\EJ-+W8AE&A#?M_6[PX_D M]V5S+7(''*@&DE*=@R(_SQA/6M%1U R/PJ@1K9LIH,8?26@.+?(NB,( *QZ3 M,&J=X'](.C?DLG CR)"EL&XKLX5BDVE.OHN_)X75A10".(<%N6*"BIA13@8V MY!](3\0-TN&.1.?6N9E9*(G;]\0_,-$"EV4MCV3CE4V MYB/%&U)-,-RC9F"-O'6;^9;18[,P"4]/3X/B:+F^9E6UL8$P^//F>A!/(:4^ M0D!H\493&$V2_V.]'MQ)L#QHZVO6TH6G:QD7N:\AB^RL8;[YMIIOBOPP\IMA M8ZX3[]PTN[7JG-!],'LRE5*8T!6<64+_M7T16.WH6G04[G M4LAT$1C[X$+&LQ1$;M\[(KD4.AG"I3%C3/6H\(0SB0FEV7+@ )YK6_)Y!%D5W ^0 1B=74ZUOAT/T7.IV?#7M=T(5,*1.'4*ZR?C&\]?NOW*_ GL!-5YG* M-)6BD'0#Z0C404BWC5^OZJ+[0 4 ]WY=28PI#Y5.)5D&>93 M3/HVD$)%?Z;B*<[6BT50?9+/;^.5 W^^0-LO3E[!&?[TM+Z#@UEB!K0K3B=U MI_4;1J_WHKL]O925"BRS'QNXS':"VU)J%Q4HRGNXMIS_!HNZ_'88.\AQAQ++ M\R=G>%KU0\QO78QE&P?IE06LH#4CYZ#U\7HA47=R@;/#0^EM&#N,<4.)Y=ET MAN=2\AU,F-F#$?D'FM;&66WK(,UJ(1;FL6,P>R*6*I.JT%RLWKIRAE>+15<[D2]!N M^7"=[Y8@"SET$W)?ZISROUAV^&*HVH/K@#?D6+SN[$B9$:BC@!X"M&SC(,*R M O-G6TG\PP>[T^E.'"]NFWG(+QM$1:@.UM-?V!\.0ASDW@F5JNR6D^T[#%V M$.4.)9:G.QM( \E9S,S]WAN\X"MF0JL'L\K209)5,BQ&=[:1^@I,7P2@7H^Y H_[J.N$&6!N[.E-(!X M9D(,H]&0Y?4>_*ZVY?S>$K%! ZY+UYMZR#%:B$6IFL[0)*G(J#CP^;$= M+AQ$NU>/)?P5-H'.@JV<8 1 " 0D0 M !D.#0T.#(R9&5X.3DQ+FAT;5!+ 0(4 Q0 ( '&'U%C L',9)P0 (X0 M 1 " ;D: !V;F1A+3(P,C0P-C$Y+GAS9%!+ 0(4 Q0 M ( '&'U%AA93]]^@4 !,V 5 " 0\? !V;F1A+3(P M,C0P-C$Y7V1E9BYX;6Q02P$"% ,4 " !QA]18ZQW?LO\' #Q60 %0 M @ $\)0 =FYD82TR,#(T,#8Q.5]L86(N>&UL4$L! A0#% M @ <8?46*O*C5FE!0 W3D !4 ( !;BT '9N9&$M,C R C-# V,3E?<')E+GAM;%!+!08 !@ & (,! !&,P ! end XML 19 d844822d8k_htm.xml IDEA: XBRL DOCUMENT 0001347178 2024-06-19 2024-06-19 0001347178 us-gaap:CommonStockMember 2024-06-19 2024-06-19 0001347178 vnda:SeriesAJuniorParticipatingPreferredStockPurchaseRightMember 2024-06-19 2024-06-19 false 0001347178 8-K 2024-06-19 VANDA PHARMACEUTICALS INC. DE 001-34186 03-0491827 2200 Pennsylvania Avenue NW Suite 300E Washington DC 20037 (202) 734-3400 false false false false Common Stock, par value $0.001 per share VNDA NASDAQ Series A Junior Participating Preferred Stock Purchase Right, par value $0.001 per share —  NASDAQ false